# Study to Assess the Efficacy of 12 Versus 24 Weeks of Extended Treatment in HCV-Genotype 2/3 Patients

> **NCT00803309** · PHASE4 · TERMINATED · sponsor: **HepNet Study House, German Liverfoundation** · enrollment: 99 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** pegylated interferon alpha-2b
- **DRUG:** Ribavirin
- **DRUG:** pegylated Interferon alpha-2b
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT00803309
- **Lead sponsor:** HepNet Study House, German Liverfoundation
- **Sponsor class:** NETWORK
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-11
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 99 (ACTUAL)
- **Why stopped:** At the end of the planned recruitment period the expected number of subjects could not be included in the trial.
- **Last updated:** 2017-08-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00803309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00803309, "Study to Assess the Efficacy of 12 Versus 24 Weeks of Extended Treatment in HCV-Genotype 2/3 Patients". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00803309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*